Molecules that bind to CD66e polypeptides
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsDimiter Stanchev Dimitrov, John W. Mellors, Dusan Baek
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to a CD66e polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to a CD66e polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.
Claims17
An antibody or antigen binding fragment thereof comprising:
- (i) a heavy chain variable domain (VH) and alight chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:1, a VH-CDR2 sequence of SEQ ID NO:
- 2, and a VH-CDR3 sequence of SEQ ID NO:
- 3, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 9, a VL-CDR2 sequence of SEQ ID NO:
- 10, and a VL-CDR3 sequence of SEQ ID NO:
- 11;
- or
- (ii) a heavy chain variable domain (VH) and alight chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:
- 17, a VH-CDR2 sequence of SEQ ID NO:
- 18, and a VH-CDR3 sequence of SEQ ID NO:
- 19, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 25, a VL-CDR2 sequence of SEQ ID NO:
- 26, and a VL-CDR3 sequence of SEQ ID NO:
- 27;
- wherein said antibody or antigen binding fragment thereof binds CD66e.
A method of treating a mammal having cancer, wherein said method comprises administering, to said mammal, a composition comprising (a) an antibody comprising (i) or (ii), (b) an antigen binding fragment comprising said (i) or said (ii), (c) a cell expressing a chimeric antigen receptor comprising an antigen binding domain comprising said (i) or said (ii), a hinge, a transmembrane domain, and one or more signaling domains, (d) a cell engager comprising a first antigen binding domain comprising said (i) or said (ii), a linker, and a second antigen binding domain, or (e) an ADC comprising a drug covalently linked to an antigen binding domain comprising said (i) or said (ii), wherein said
- (i) is a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:
- 1, a VH-CDR2 sequence of SEQ ID NO:
- 2, and a VH-CDR3 sequence of SEQ ID NO:
- 3, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 9, a VL-CDR2 sequence of SEQ ID NO:
- 10, and a VL-CDR3 sequence of SEQ ID NO:
- 11, and wherein said
- (ii) is a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:
- 17, a VH-CDR2 sequence of SEQ ID NO:
- 18, and a VH-CDR3 sequence of SEQ ID NO:
- 19, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 25, a VL-CDR2 sequence of SEQ ID NO:
- 26, and a VL-CDR3 sequence of SEQ ID NO:
- 27;
- wherein said antibody, antigen binding fragment, cell, cell engager, or ADC binds CD66e.
A method for binding a binding molecule to a CD66e polypeptide, wherein said method comprises contacting said CD66e polypeptide with (a) a chimeric antigen receptor comprising an antigen binding domain comprising (i) or (ii), a hinge, a transmembrane domain, and one or more signaling domains, (b) a cell engager comprising a first antigen binding domain comprising said (i) or said (ii), a linker, and a second antigen binding domain, or (c) an ADC comprising a drug covalently linked to an antigen binding domain comprising said (i) or said (ii), wherein said
- (i) is a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:
- 1, a VH-CDR2 sequence of SEQ ID NO:
- 2, and a VH-CDR3 sequence of SEQ ID NO:
- 3, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 9, a VL-CDR2 sequence of SEQ ID NO:
- 10, and a VL-CDR3 sequence of SEQ ID NO:
- 11, and wherein said
- (ii) is a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein said VH comprises a VH-CDR1 sequence of SEQ ID NO:
- 17, a VH-CDR2 sequence of SEQ ID NO:
- 18, and a VH-CDR3 sequence of SEQ ID NO:
- 19, and said VL comprises a VL-CDR1 sequence of SEQ ID NO:
- 25, a VL-CDR2 sequence of SEQ ID NO:
- 26, and a VL-CDR3 sequence of SEQ ID NO:
- 27;
- wherein said chimeric antigen receptor, cell engager, or ADC binds CD66e.
Dependencies are inferred from the claim text.